酵素阻害剤の世界市場

酵素阻害剤の世界市場は2030年までに40億米ドルに達する見込み

2024年に29億米ドルと推定される酵素阻害剤の世界市場は、2024年から2030年にかけてCAGR 5.5%で成長し、2030年には40億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである低分子阻害剤は、CAGR7.5%を記録し、分析期間終了時には16億米ドルに達すると予想されます。モノクローナル抗体セグメントの成長率は、分析期間中CAGR 3.7%と推定されます。

米国市場は7億9,260万米ドルと推定、中国はCAGR 9.1％で成長すると予測

米国の酵素阻害剤市場は、2024年には7億9,260万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8億2,350万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5%と5.6%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の酵素阻害剤市場- 主要動向と促進要因のまとめ

酵素阻害剤が現代の医薬品開発の中心になりつつあるのはなぜか？

酵素阻害剤分野は、現代の創薬や治療介入において極めて重要な役割を担っているため、過去10年間で大きな注目を集めてきました。酵素阻害剤-酵素に結合し、その活性を低下させる分子-は、がんや心血管疾患から神経変性疾患や感染症に至るまで、様々な疾患の治療において不可欠なツールとなっています。生物学的経路を正確に調節するその能力は、標的治療の理想的な候補となります。最も大きな影響を及ぼしているのは腫瘍学であり、プロテアーゼ阻害剤とキナーゼ阻害剤は治療パラダイムに革命をもたらし、がん管理に対する高度に個別化されたアプローチを可能にしています。同様に、酵素阻害は抗ウイルス療法に不可欠であり、特にHIVや肝炎ではウイルスの複製サイクルを破壊します。疾病に関連した代謝経路やシグナル伝達経路のマッピングを続けることにより、新たな酵素標的が明らかになり、新規阻害剤のパイプラインが広がっています。X線結晶構造解析や極低温電子顕微鏡などの構造生物学の進歩は、酵素と阻害剤の相互作用を原子レベルの分解能で理解することを加速しています。人工知能や機械学習と相まって、これらの洞察は精度と効率を高めた合理的な薬剤設計を可能にしています。さらに、バイオ製薬企業は酵素阻害剤プラットフォームに多額の投資を行っており、その結果、臨床試験に入る治験薬（IND）が急増しています。広範な治療からメカニズムに特化した薬剤へのシフトは、酵素阻害剤を次世代治療薬の要として位置づけています。

酵素阻害剤を取り巻く規制状況と臨床状況はどのように進化しているか？

酵素阻害剤を管理する規制と臨床の枠組みは、これらの分子の複雑さと特異性に対応するために適応しつつあります。米国FDAやEMAのような規制機関は、特にアンメット・クリニカル・ニーズの領域において、有望な候補薬に対してファスト・トラック指定、希少疾病用医薬品（オーファンドラッグ）ステータス、早期承認を提供することで、酵素阻害剤のユニークな治療価値をますます認めています。このような規制開放の進展は、初期段階のバイオテクノロジー企業に、以前は有効な治療法がなかったニッチな適応症への投資を促しています。臨床面では、遺伝子やプロテオミクスのプロファイルに基づく患者層別化によって、酵素阻害療法が最も有効な患者を特定するバイオマーカー主導型試験が重視されるようになっています。このプレシジョン・メディシン・アプローチは、試験中止率を減少させ、後期段階での成功確率を向上させています。しかしながら、安全性プロファイルは依然として重大な懸念事項です。多くの酵素阻害剤が中枢代謝経路を阻害することから、その標的外作用は深刻なものとなりうる。このため、より厳格な前臨床検証プロセスや、毒性リスクを最小化する高度なスクリーニング・プラットフォームの採用につながっています。さらに、ファーマコゲノミクスの統合により、酵素阻害剤に対する患者固有の反応についての理解が深まり、より個別化された投与レジメンへの道が開かれつつあります。知的財産のダイナミクスも競合情勢を形成しており、新規の足場、アイソフォーム選択的阻害剤、独自の製剤技術に関する特許出願が増加しています。このような動向は、規制・臨床環境がより協力的であるだけでなく、より厳しいものとなり、開発者をより高い基準の有効性、安全性、特異性へと押し上げていることを裏付けています。

市場の多様化において、新興技術や新たな治療領域が果たす役割とは？

新興テクノロジーと非伝統的治療領域への拡大は、酵素阻害剤市場を大きく多様化しています。CRISPRのような遺伝子編集ツールや先進オミックス技術は、以前は治療不可能と考えられていた新たな生物学的標的を明らかにしています。ヒストン脱アセチル化酵素（HDAC）やDNAメチル化酵素（DNMT）といったエピジェネティック酵素の阻害剤は、特にがんや稀な遺伝性疾患において、異常な遺伝子発現パターンを逆転させる能力で人気を集めています。さらに、酵素阻害と免疫療法の交差点は急速に発展している領域であり、阻害剤を用いて免疫チェックポイントや免疫細胞の代謝経路を調節し、抗腫瘍反応を増強することが行われています。腫瘍学にとどまらず、アルツハイマー病やパーキンソン病などの神経変性疾患も、酵素の調節、特にアミロイド前駆体の処理や神経炎症に関与する酵素の調節という切り口で研究されています。抗菌剤耐性もまた、細菌のβ-ラクタマーゼを阻害する酵素阻害剤への関心を煽り、既存の抗生物質の効力を活性化させています。技術的には、ハイスループットスクリーニング（HTS）、コンピューター支援薬物設計（CADD）、フラグメントベースの創薬（FBDD）の採用により、リード化合物の同定と最適化が効率化されています。これらの手法により、迅速な反復と改良が可能になり、医薬品開発のスピードと成功率の両方が向上しています。さらに、合成生物学とペプチド工学の台頭は、安定性と組織特異性を改善した生物工学的阻害剤の機会を生み出しています。これらの技術革新は、酵素阻害剤の治療視野を広げるだけでなく、創薬、検証、上市の方法も再定義しつつあります。

酵素阻害剤市場の加速的拡大の原動力は？

酵素阻害剤市場の成長は、技術革新、治療需要、戦略的市場力学に関連するいくつかの要因によって牽引されています。主な促進要因は、がん、自己免疫疾患、代謝異常などの慢性的で複雑な疾患の有病率の上昇であり、酵素阻害剤が独自に提供するメカニズムに特化した治療が必要とされています。拡大する計算生物学とAIの能力は、これまでにないスピードで新規酵素ターゲットの発見と分子設計の最適化を促進し、研究開発サイクルのコストと期間を削減しています。患者ゲノムデータの利用可能性が高まることで、より正確な標的検証と患者セグメンテーションが可能になり、臨床転帰が改善され、市場への浸透が進んでいます。最終用途の観点からは、生物学的標的治療への戦略的シフトを反映し、バイオ製薬企業がコアパイプラインの一部として酵素阻害剤に多額の投資を行っています。さらに、アカデミアと産業界の連携によりトランスレーショナル研究が強化され、ベンチサイドからベッドサイドへの移行が加速しています。患者や医療提供者は、より特異性が高く、全身的な副作用が少ない治療法を好むようになっており、これは酵素阻害剤の薬理学的プロファイルによく合致しています。酵素阻害剤が免疫療法や従来の薬剤と一緒に使用される併用療法の出現は、その臨床適用性と市場価値をさらに拡大しています。アジア太平洋やラテンアメリカにおけるヘルスケア支出の増加といった地域的要因や、新興国市場における有利な償還政策が、世界の広がりをもたらしています。これらすべての相互連関する力が収束し、酵素阻害剤分野での継続的な革新、採用、成長のための肥沃な環境が整いつつあります。

セグメント

製品タイプ（低分子阻害剤、モノクローナル抗体、RNAベースの阻害剤、その他の製品タイプ）、治療領域（がん、心血管疾患、感染症、自己免疫疾患、その他の治療領域）、エンドユーザー（製薬企業、バイオテクノロジー企業、学術・研究機関）

調査対象企業の例（合計 34社を掲載）

• Abbott Laboratories
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Cipla Limited
• Daiichi Sankyo Co., Ltd.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Incyte Corporation
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Ranbaxy Laboratories Limited
• Sanofi
• Takeda Pharmaceutical Company

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Enzyme Inhibitors Market to Reach US$4.0 Billion by 2030

The global market for Enzyme Inhibitors estimated at US$2.9 Billion in the year 2024, is expected to reach US$4.0 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Small Molecule Inhibitors, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Monoclonal Antibodies segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$792.6 Million While China is Forecast to Grow at 9.1% CAGR

The Enzyme Inhibitors market in the U.S. is estimated at US$792.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$823.5 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Enzyme Inhibitors Market - Key Trends & Drivers Summarized

Why Are Enzyme Inhibitors Becoming Central to Modern Drug Development?

The field of enzyme inhibitors has garnered substantial attention over the past decade due to its pivotal role in modern drug discovery and therapeutic intervention. Enzyme inhibitors-molecules that bind to enzymes and reduce their activity-have become essential tools in the treatment of diseases ranging from cancer and cardiovascular conditions to neurodegenerative and infectious diseases. Their ability to precisely modulate biological pathways makes them ideal candidates for targeted therapy. One of the most profound impacts has been seen in oncology, where protease and kinase inhibitors have revolutionized treatment paradigms, enabling highly personalized approaches to cancer management. Similarly, enzyme inhibition is integral to antiviral therapies, particularly in HIV and hepatitis, where it disrupts the replication cycles of viruses. The continued mapping of disease-related metabolic and signaling pathways is unveiling new enzyme targets, expanding the pipeline for novel inhibitors. Advances in structural biology, including X-ray crystallography and cryo-electron microscopy, have accelerated the understanding of enzyme-inhibitor interactions at atomic resolution. Coupled with artificial intelligence and machine learning, these insights are enabling rational drug design with enhanced precision and efficiency. Moreover, biopharmaceutical companies are heavily investing in enzyme inhibitor platforms, resulting in a surge of investigational new drugs (INDs) entering clinical trials. The shift from broad-spectrum treatments to mechanism-specific drugs is positioning enzyme inhibitors as a cornerstone in next-generation therapeutics.

How Are Regulatory and Clinical Landscapes Evolving Around Enzyme Inhibitors?

The regulatory and clinical frameworks governing enzyme inhibitors are adapting to accommodate the complexity and specificity of these molecules. Regulatory agencies such as the U.S. FDA and EMA have increasingly acknowledged the unique therapeutic value of enzyme inhibitors by offering fast-track designations, orphan drug statuses, and accelerated approvals for promising candidates, especially in areas of unmet clinical need. This evolving regulatory openness has encouraged early-phase biotech firms to invest in niche indications that previously lacked viable treatments. Clinically, there is a growing emphasis on biomarker-driven trials, where patient stratification based on genetic or proteomic profiles is helping to identify those most likely to benefit from enzyme inhibition therapy. This precision-medicine approach is reducing trial attrition rates and improving success probabilities in later phases. However, safety profiles remain a critical concern-given that many enzyme inhibitors interfere with central metabolic pathways, their off-target effects can be severe. This has led to more stringent preclinical validation processes and the adoption of advanced screening platforms that minimize toxicity risks. Additionally, the integration of pharmacogenomics is enhancing understanding of patient-specific responses to enzyme inhibitors, paving the way for more personalized dosage regimens. Intellectual property dynamics are also shaping the competitive landscape, with an increasing number of patent applications being filed for novel scaffolds, isoform-selective inhibitors, and proprietary formulation technologies. These trends underscore a regulatory and clinical environment that is not only more supportive but also more demanding, pushing developers toward higher standards of efficacy, safety, and specificity.

What Role Do Emerging Technologies and New Therapeutic Areas Play in Market Diversification?

Emerging technologies and the expansion into non-traditional therapeutic areas are significantly diversifying the enzyme inhibitors market. Gene editing tools like CRISPR and advanced omics technologies are unveiling new biological targets that were previously considered undruggable. Inhibitors of epigenetic enzymes such as histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) are gaining traction for their ability to reverse aberrant gene expression patterns, especially in cancer and rare genetic disorders. Additionally, the intersection of enzyme inhibition and immunotherapy is a rapidly evolving space, where inhibitors are being used to modulate immune checkpoints or metabolic pathways in immune cells to enhance anti-tumor responses. Beyond oncology, neurodegenerative diseases such as Alzheimer’s and Parkinson’s are now being explored through the lens of enzyme modulation-particularly enzymes involved in amyloid precursor processing or neuroinflammation. Antibacterial resistance is also fueling interest in enzyme inhibitors that can block bacterial beta-lactamases, thus revitalizing the efficacy of existing antibiotics. Technologically, the adoption of high-throughput screening (HTS), computer-aided drug design (CADD), and fragment-based drug discovery (FBDD) is streamlining the identification and optimization of lead compounds. These methodologies allow for rapid iteration and refinement, improving both the speed and success rate of drug development. Moreover, the rise of synthetic biology and peptide engineering is creating opportunities for bioengineered inhibitors with improved stability and tissue specificity. These innovations are not only broadening the therapeutic horizons of enzyme inhibitors but are also redefining how they are discovered, validated, and brought to market.

What’s Fueling the Accelerated Expansion of the Enzyme Inhibitors Market?

The growth in the enzyme inhibitors market is driven by several factors related to technological innovation, therapeutic demand, and strategic market dynamics. A primary driver is the rising prevalence of chronic and complex diseases such as cancer, autoimmune conditions, and metabolic disorders, which necessitate mechanism-specific treatments that enzyme inhibitors uniquely provide. The expanding capabilities of computational biology and AI are facilitating the discovery of novel enzyme targets and optimizing molecular designs at unprecedented speeds, reducing the cost and duration of R&D cycles. The growing availability of patient genomic data is enabling more accurate target validation and patient segmentation, improving clinical outcomes and increasing market penetration. From an end-use perspective, biopharmaceutical firms are investing heavily in enzyme inhibitors as part of their core pipelines, reflecting a strategic shift toward biologically targeted therapies. Additionally, partnerships between academia and industry are enhancing translational research, resulting in a faster transition from bench to bedside. Consumer behavior is also playing a role-patients and healthcare providers are increasingly favoring therapies that offer higher specificity with fewer systemic side effects, aligning well with the pharmacological profile of enzyme inhibitors. The emergence of combination therapies, where enzyme inhibitors are used alongside immunotherapies or conventional drugs, is further expanding their clinical applicability and market value. Regional factors, such as increased healthcare spending in Asia-Pacific and Latin America, along with favorable reimbursement policies in developed markets, are contributing to a broader global footprint. All these interconnected forces are converging to create a fertile landscape for continued innovation, adoption, and growth within the enzyme inhibitors sector.

SCOPE OF STUDY:

The report analyzes the Enzyme Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors, Other Product Types); Therapeutic Area (Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders, Other Therapeutic Areas); End-Use (Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Cipla Limited
• Daiichi Sankyo Co., Ltd.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Incyte Corporation
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Ranbaxy Laboratories Limited
• Sanofi
• Takeda Pharmaceutical Company

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Enzyme Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Chronic Diseases Propels Growth in Demand for Targeted Enzyme Inhibitors
  • Advancements in Drug Discovery Technologies Expand the Addressable Market for Enzyme-Based Therapeutics
  • Personalized Medicine Initiatives Drive Adoption of Selective Enzyme Inhibitor Therapies
  • Aging Global Population Throws the Spotlight on Age-Related Enzyme-Linked Disorders
  • Biopharmaceutical Innovation Strengthens the Business Case for Next-Generation Enzyme Inhibitors
  • Increased Focus on Rare and Orphan Diseases Accelerates Demand for Novel Enzyme Inhibition Strategies
  • Growing Investment in Oncology Research Spurs Development of Cancer-Specific Enzyme Inhibitors
  • Shift Toward Combination Therapies Drives Integration of Enzyme Inhibitors into Multi-Drug Regimens
  • Rising Antimicrobial Resistance Throws the Spotlight on Enzyme Inhibitors as Alternative Therapeutics
  • Expanding Applications in Metabolic Disorders Sustain Growth of Enzyme Inhibitor Pipelines
  • Emergence of Biologics and Peptide-Based Inhibitors Redefines the Competitive Landscape
  • Growing Demand for High-Specificity Drugs Drives Innovation in Structure-Based Enzyme Inhibitor Design
  • Technological Advancements in Computational Biology Propel Discovery of Novel Enzyme Targets
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Enzyme Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Enzyme Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Enzyme Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Enzyme Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecule Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Small Molecule Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Small Molecule Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for RNA-based Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for RNA-based Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for RNA-based Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Autoimmune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Autoimmune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Autoimmune Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• JAPAN
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• CHINA
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• EUROPE
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Enzyme Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Enzyme Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Enzyme Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• FRANCE
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• GERMANY
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Enzyme Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Enzyme Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• INDIA
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Enzyme Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Enzyme Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Enzyme Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Enzyme Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Enzyme Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Enzyme Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• AFRICA
  • Enzyme Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Enzyme Inhibitors by Product Type - Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Enzyme Inhibitors by Product Type - Percentage Breakdown of Value Sales for Small Molecule Inhibitors, Monoclonal Antibodies, RNA-based Inhibitors and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Enzyme Inhibitors by End-Use - Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Enzyme Inhibitors by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotechnology Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Enzyme Inhibitors by Therapeutic Area - Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Enzyme Inhibitors by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030

IV. COMPETITION